Kobayashi Hiroaki, Yanazume Shintaro, Kamio Masaki, Togami Shinichi, Ushiwaka Takashi
Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.
Int J Clin Oncol. 2025 May;30(5):1002-1017. doi: 10.1007/s10147-025-02718-0. Epub 2025 Mar 5.
The importance of minimally invasive fertility-sparing surgery for cervical cancer is gaining increasing interest, both to achieve a cure and for future fertility. Procedures for robotic radical trachelectomy involving uterine reconstruction are not fully established.
This study prospectively verified the feasibility and safety of robotic radical trachelectomy between February 2018 and May 2022. The criteria were almost identical to those for our standard abdominal radical trachelectomy. Larger tumors (> 2 cm in diameter) were acceptable for surgery, provided a secure ≥ 1 cm cancer-free space was identified between the tumor and internal os.
Eight patients (median age, 32 y) were registered; the median body mass index was 21.8, and the median tumor size was 11.5 mm (range 0-30 mm). Robotic radical trachelectomy could be achieved in all patients with hybrid sentinel lymph node navigation surgery, confirming the precise cervical amputation line with a newer small knob ultrasonography probe, adequate cervical cerclage with non-absorbable monofilament stitches, and avoiding looseness between vaginal-uterine anastomosis with uninterrupted barbed U-shaped sutures. None of the cases were converted to laparotomy or radical hysterectomy, and there were no major complications. The median follow-up period was 49.5 mo (range 21-58 mo) and no patient had disease recurrence.
Robotic radical trachelectomy is safe and feasible using newer technologies without reducing radicality; it is also less invasive. Procedures are consistently reproducible and have the potential to be generalized to minimally invasive approaches.
微创保留生育功能手术治疗宫颈癌的重要性日益受到关注,其目的在于实现治愈以及保留未来生育能力。涉及子宫重建的机器人根治性宫颈切除术的手术方法尚未完全确立。
本研究前瞻性地验证了2018年2月至2022年5月期间机器人根治性宫颈切除术的可行性和安全性。纳入标准与我们的标准腹部根治性宫颈切除术几乎相同。对于直径>2 cm的较大肿瘤,如果在肿瘤与子宫颈内口之间能确定≥1 cm的无癌安全切缘,则可进行手术。
共纳入8例患者(中位年龄32岁);中位体重指数为21.8,中位肿瘤大小为11.5 mm(范围0 - 30 mm)。所有患者均成功实施了机器人根治性宫颈切除术及混合前哨淋巴结导航手术,使用新型小探头超声检查仪确定了精确的宫颈切除线,采用不可吸收单丝缝线进行了充分的宫颈环扎,并使用连续倒刺U形缝线避免阴道 - 子宫吻合口松弛。无一例转为开腹手术或根治性子宫切除术,也未发生严重并发症。中位随访期为49.5个月(范围21 - 58个月),无患者疾病复发。
使用新技术进行机器人根治性宫颈切除术是安全可行的,且不降低根治性;其创伤性也较小。手术操作具有一致性和可重复性,有可能推广至微创治疗方法。